DrugBank

MAY 22, 2024

In the dynamic world of drug discovery, the notion of "undruggable" targets presents both a significant challenge and an intriguing frontier for researchers and pharmaceutical companies. Strategies to Tackle PPIs Despite these challenges, some wins in targeting PPIs with small molecules have emerged.

Small Molecule 96

Small Molecule RNA DNA Pharmaceutical Companies 96

DrugBank

OCTOBER 17, 2024

By harnessing the vast amounts of data generated throughout the development pipeline, pharmaceutical companies can accelerate the discovery of novel therapies, optimize clinical trial design, enhance drug safety monitoring, and deliver personalized medicine, ultimately improving patient outcomes and transforming the future of healthcare.

Drug Development 98

Drug Development Metabolic Stability Clinical Trials Drugs 98

Conversations in Drug Development Trends

APRIL 4, 2024

Developing pharmaceuticals is a complex process, requiring stringent bioanalytical method validation guidelines to ensure drug safety and efficacy. To help integrate these various regulatory standards, the International Council for Harmonization (ICH) of Technical Requirements for Pharmaceuticals for Human Use was founded in 2016.

Small Molecule 80

Small Molecule Clinical Trials Pharmaceuticals Pharmaceutical Companies 80

The Pharma Data

JANUARY 19, 2021

Dr. Clark Cheng, Chief Medical Officer and Executive Director of Aptorum Group, commented, “The clearance of our CTA application for ALS-4 drug represents a significant milestone for the company and one of a number of targeted strategic goals for 2021. About ALS-4. About Aptorum Group.

Small Molecule 52

Small Molecule Clinical Trials Trials Pharmacokinetics 52

The Pharma Data

NOVEMBER 19, 2020

To date, the Company has applied its world-leading structure-based drug design (SBDD) capabilities and cutting-edge technologies to precision-design new inhibitors of the SARS-CoV-2 M pro protease, which plays a crucial role in viral replication 1-4.

Small Molecule 40

Small Molecule Structure Based Drug Design (SBDD) Molecular Biology International 40

The Pharma Data

NOVEMBER 30, 2020

Biohaven acquires exclusive global rights to a portfolio of novel, small-molecule CGRP antagonists. NURTEC is a trademark of Biohaven Pharmaceutical Ireland DAC. Sosei Heptares will receive an upfront payment of US$10 million, plus downstream payments of up to US$370 million, plus tiered royalties.

Small Molecule 40

Small Molecule Licensing Licensing Treatment 40

Drug Target Review

JUNE 19, 2024

Also, many companies never reached the point where they received validation from big pharmaceutical companies. Transplanting cells could prove to be more beneficial than treating a particular condition with a small molecule or an antibody, and that really speaks to the power of cell therapy.

Therapies 84

Therapies Small Molecule Pharmaceutical Companies Molecular Biology 84

Drug Target Review

JULY 18, 2023

If we look at the pharmaceutical industry’s discovery and development success rate over the last 20 to 30 years, it has not improved, staying stubbornly at around 10 percent. With support from pharmaceutical companies, ultimately, the answer to this question should be yes. Will systems like the NHS be able to deliver it?

Drug Development 98

Drug Development Drugs Clinical Development Pharmaceutical Companies 98

KIF1A

JULY 1, 2023

Making drug repositioning a part of therapeutic development is a complicated endeavor relying on interactions between regulatory bodies, pharmaceutical companies, rare disease researchers, and patients. It requires a deep look at former products that ended at various stages of research and development.

Small Molecule 98

Small Molecule FDA Approval Disease Pharmaceutical Companies 98

The Pharma Data

NOVEMBER 29, 2020

(Headquarters: Cambridge, UK, “Wren”) today announced that the companies have entered into an exclusive research collaboration agreement aiming to advance the discovery of novel small molecules that target ?-synuclein is a leading global research and development-based pharmaceutical company headquartered in Japan.

Small Molecule 52

Small Molecule Research Pharmaceutical Companies Drugs 52

The Pharma Data

SEPTEMBER 22, 2020

We are delighted to close this deal with Roche, an outstanding pharmaceutical company with a broad commitment to multiple indications,” said Matt Cooper, chief executive officer of Inflazome. Roche has plans to further develop Inflazome’s products across a wide range of indications with high unmet medical need.

Pharma Companies 52

Pharma Companies Small Molecule Pharmaceutical Companies Disease 52

The Pharma Data

AUGUST 7, 2021

(Vividion), a US-headquartered biopharmaceutical company utilizing novel discovery technologies to unlock high value, traditionally undruggable targets with precision therapeutics. Vividion’s platform is able to produce a variety of small molecule therapies across indications, with initial focus on targets relevant to oncology and immunology.

Small Molecule 52

Small Molecule Drugs Therapies Disease 52

Drug Target Review

APRIL 19, 2024

Sibylla’s scientific founders come from very different scientific fields that do not usually speak to each other, such as theoretical physics, molecular biology and pharmaceutical chemistry. We also have collaborations with pharmaceutical companies where we leverage the best of our unique platform and pharma expertise on the target.

Molecular Biology 111

Molecular Biology Research Pharmaceuticals Small Molecule 111

Practical Cheminformatics

JANUARY 8, 2024

While large pharmaceutical companies have data on thousands or even millions of compounds, this data is rarely shared due to intellectual property concerns. Data from 21 million molecules and more than 40,000 assays was securely combined into a multitask model. For classification models, the participants reported a median 2.5-7.5%

Drugs 136

Drugs Small Molecule Bioinformatics Packaging 136

The Strateos Blog: Drug Discovery

AUGUST 16, 2021

To advance a lead candidate through to clinical trials in traditional small molecule pipelines, it can take on average 6+ years. We will discuss the integration of the PerkinElmer Signals Notebook with Strateos’s powerful automated synthesis system to drive efficient synthesis of druglike compounds. " - Vince Yeh, Ph.D.,

Synthetic Chemistry 52

Synthetic Chemistry Small Molecule Drugs Clinical Trials 52

The Pharma Data

JULY 15, 2021

JJIPO@Monash was originally launched in 2018 to provide crucial support to researchers and companies in the Victorian life-science sector as part of the Government’s commitment to the medical technologies and pharmaceuticals sector – one of eight priority growth sectors.

Government 52

Government Science Pharmaceuticals Pharmaceutical Companies 52

The Pharma Data

OCTOBER 27, 2020

APRINOIA Therapeutics is currently advancing a pipeline featuring diagnostic and therapeutic programs, collectively targeting brain disorders associated with abnormal accumulation of pathological proteins, including tau and alpha-synuclein, from its proprietary small molecule and antibody discovery platforms.

Clinical Trials 40

Clinical Trials Trials Small Molecule Pharmaceutical Companies 40

The Pharma Data

MAY 2, 2023

Starting in 2026, this facility will develop manufacturing processes for active pharmaceutical ingredients and produce drugs for use in clinical trial phases. This step is crucial for Boehringer Ingelheim to rapidly advance new drug candidates from the company’s vast research pipeline to clinical trials and ultimately to market approval.

Small Molecule 40

Small Molecule Clinical Trials Pharmaceuticals Pharmaceutical Companies 40

The Pharma Data

DECEMBER 13, 2020

Since its establishment, Viva Biotech has been providing comprehensive new drug R&D services to nearly 500 world’s top pharmaceutical and biotech companies based on Viva’s excellence in structure-based drug discovery.

Small Molecule 40

Small Molecule Computational Chemistry Pharmaceuticals Production 40

Drug Target Review

MAY 23, 2023

Algae – an overlooked resource for new therapies It is only in recent years that algae research has expanded beyond their potential for producing biodiesel, to also consider them as a bio-resource, not only for novel prebiotics but also for compounds with unique structures and pharmaceutically relevant bioactivities.

Drugs 75

Drugs Small Molecule Production Disease 75

New Drug Approvals

SEPTEMBER 10, 2024

g/mol 1929519-13-0 NBI-1065846 or TAK-041 Phase 2 (S)-2-(4-oxobenzo[d][1,2,3]triazin-3(4H)-yl)-N-(1-(4-(trifluoromethoxy)phenyl)ethyl)acetamide Zelatriazin ( NBI-1065846 or TAK-041 ) is a small-molecule agonist of GPR139. Zelatriazin, C 18 H 15 F 3 N 4 O 3 , 392.3 X H NMR (500 MHz, DMSO-i¾) δ ppm 1.40 (d, J=6.8

Clinical Pharmacology 62

Clinical Pharmacology Small Molecule Pharmacokinetics Pharmaceutical Companies 62

The Pharma Data

DECEMBER 21, 2020

Program focused on identifying small molecules that target a GPCR for degradation as potential therapeutic agents for gastrointestinal disorders. The principle of TPD is to use small molecules to commit the target protein into the E3 ligase-mediated degradation pathway thereby eliminating or reducing its activity.

Targeted Protein Degradation 40

Targeted Protein Degradation Small Molecule Structure Based Drug Design (SBDD) Drugs 40

The Pharma Data

APRIL 6, 2021

The product is developed jointly by Bayer and Orion Corporation, a globally operating Finnish pharmaceutical company. o Abstract 1470; April 10, 8:30am EDT. • Enhancement of anti-tumor T-cell immunity by means of an oral small molecule targeting the intracellular immune checkpoint MAP4K1. About Oncology at Bayer.

Research 52

Research Small Molecule Treatment Clinical Trials 52

The Pharma Data

DECEMBER 15, 2020

(hereinafter referred to as: CHIPSCREEN BIOSCIENCES) and ZHEJIANG HISUN PHARMACEUTICAL CO., hereinafter referred to as: HISUN PHARMACEUTICAL) announced that they have reached a strategic cooperation. SH) was founded in Shenzhen on 2001, specializing in the research and development of novel small molecule drugs.

Pharmaceuticals 40

Pharmaceuticals Clinical Trials Small Molecule Disease 40

The Pharma Data

APRIL 7, 2023

This is a fine balance to achieve – if the compounds are too large, they may not pass through the cell membrane, and their bioavailability would be affected; if they are too small, they would not retain high specificity to the target protein (or proteins).

Small Molecule 40

Small Molecule Drugs Pharmaceutical Companies Research 40

The Pharma Data

AUGUST 21, 2020

It’s a coalition of globally renowned academic institutions, pharmaceutical companies and nonprofit research organizations. Novartis has agreed to contribute a carefully curated library of about 1300 small molecules with antiviral activity to the CARE project. CARE stands for Corona Accelerated R&D in Europe.

Virus 52

Virus Small Molecule Licensing Licensing 52

Elrig

APRIL 29, 2024

Harini Srinivasan is a Principal Scientific Associate at Serna Bio with over 10 years of research experience in academic institutions, health care organizations and pharmaceutical companies. There, I supported AI-enabled DD efforts in their small molecule portfolio.

Bioinformatics 59

Bioinformatics Drugs Molecular Biology Cell Based Assays 59

NIH Director's Blog: Drug Development

APRIL 7, 2015

After a whirlwind tour of the cutting-edge robotics facility for high throughput screening of small molecules, she joined me and NCATS Director Dr. Chris Austin in announcing that, thanks to an innovative public-private partnership, an experimental drug originally developed to fight cancer is now showing promise against Alzheimer’s disease.

Disease 40

Disease Drugs Clinical Trials Science 40

The Pharma Data

JANUARY 17, 2021

Calliditas Therapeutics is a specialty pharmaceutical company based in Stockholm, Sweden focused on identifying, developing and commercializing novel treatments in orphan indications, with an initial focus on renal and hepatic diseases with significant unmet medical needs. About Calliditas.

Trials 40

Trials Clinical Trials Pharmacokinetics Small Molecule 40

Dark Matter Blog

AUGUST 27, 2020

A few years ago, at Arrakis Therapeutics, we set out to conquer a strange new territory, drugging RNA structures with small molecules. In fact, it was these early pharmaceutical successes that gave us the confidence that we would ultimately succeed in systematically drugging a wide range of RNA structures.

Small Molecule 52

Small Molecule RNA Clinical Trials Drugs 52

Agency IQ

FEBRUARY 23, 2024

Additionally, this approach is generally no longer applicable to new treatments that are more targeted in their effects, such as immunotherapies and targeted small molecule therapies. This has spawned a movement focused on optimizing dose selection in oncology drug development.

Science 40

Science FDA Trials Clinical Pharmacology 40

The Pharma Data

NOVEMBER 15, 2020

R&D collaboration building on Lead Pharma’s expertise in the discovery, design and optimization of small molecule treatments. Lead Pharma is a pharmaceutical company focusing on the discovery and development of innovative medicines for the treatment of immune diseases and cancer. About Lead Pharma.

Small Molecule 52

Small Molecule Licensing Licensing Disease 52

The Pharma Data

JANUARY 19, 2021

Precision medicine developer Kura Oncology is positioned to make a meaningful difference in the treatment of cancer in the next few years with its two, wholly-owned, small molecule compounds. Photo courtesy of Kura. It’s in the spotlight, the data is stunning, and it has a lot of promise,” Troy Wilson, Ph.D., CEO, told BioSpace.

Small Molecule 52

Small Molecule Therapies FDA Approval Trials 52

DrugBank

AUGUST 15, 2024

To effectively navigate this ecosystem and expedite the development of new therapies, collaboration between the pharmaceutical industry and academia is proving increasingly vital. This includes funding large-scale clinical trials and establishing robust manufacturing/distribution networks.

Drug Development 98

Drug Development Clinical Trials Drugs Therapies 98

Drug Target Review

APRIL 16, 2024

Peptides are relatively small molecules compared to mAbs, making them easier and less costly to produce and modulate. Nevertheless, mAbs are often considered superior to peptides or small molecules in RLT if their long accumulation and excretion profile could be accelerated.

Small Molecule 59

Small Molecule Therapies Treatment Pharmaceutical Companies 59

Drug Target Review

JULY 7, 2023

It normally binds to and recycles internalised immunoglobin G (IgG) antibodies, which are important for fighting infections, as well as albumin, which helps move many small molecules through the blood. Current Pharmaceutical Design. References Prevalence of rare diseases by alphabetical list [Internet]. 2021 [cited 2023Feb28].

Disease 98

Disease Immune Response Therapies Treatment 98

DrugBank

FEBRUARY 26, 2025

In response, researchers and pharmaceutical companies are exploring novel approaches to antibiotic development. Over the past two decades, many pharmaceutical companies have deprioritized antibiotic research due to high development costs and lower profitability compared to treatments for chronic diseases.

Therapies 52

Therapies Pharmaceutical Companies Pharmacokinetics Treatment 52